Articles

People with diabetes are more sensitive to increased inflammatory response, contributing to a fast spread of COVID-19 infection. 

Canagliflozin, an SGLT2 inhibitor, and its impact in reducing hospitalizations and health care costs in people with type 2 diabetes.

Metformin's primary safety concern in patients with impaired renal function is its ability to cause lactic acidosis. 

Systemic review shows sex, age, comorbid conditions, insulin use, and several out-of-range lab predictors on hospital admission, all play a role in COVID-19 severity.

Glucose-lowering medication can influence COVID-19 pathogenesis and could have implications for treating patients with diabetes and COVID-19.

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Blood sugar levels of 70 to 160 mg/dL are considered normal, and anything outside these levels could negatively affect patients.

Are socioeconomic factors and obesity independently related to diabetes prevalence?

Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.